Low-dose yellow fever vaccine non-inferior to standard dose
1. This randomized controlled trial conducted in Kenya and Uganda assessed whether fractional doses of the 17D-204 yellow fever vaccine...
Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines
1. In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on second-generation...
Recognition of kidney allograft microvascular inflammation refines risk stratification for allograft outcomes
1. Patients with a nonrejection-related diagnosis according to the 2019 Banff classification who were reclassified as MVI, DSA-negative, and C4d-negative...
Adjunctive middle meningeal artery embolization superior to standard care in symptomatic chronic subdural hematomas
1. In this randomized controlled trial, middle meningeal artery embolization demonstrated a decreased risk of treatment failure in patients with...
Emerging highly pathogenic avian influenza A(H5N1) infections in humans
1. In this case series, of the reported 46 case-patients, 45 cases were due to exposures to infected poultry or...
Infigratinib shows promising efficacy and tolerability in pediatric achondroplasia
1. In this phase two dose-finding study in children with achondroplasia, daily oral Infigratinib did not lead to any grade...
CAR+ T-cell lymphoma linked to cilta-cel therapy in myeloma
1. This study describes two cases of malignant monoclonal T-cell lymphoproliferation following ciltacabtagene autoleucel (cilta-cel) Chimeric Antigen Receptor T-cell (CAR...
Abelacimab reduces bleeding risk compared to rivaroxaban in atrial fibrillation
1. In this randomized controlled trial, abelacimab led to significantly lower rates of major or clinically relevant nonmajor bleeding compared...
Intraosseous and intravenous vascular access are equally effective for ROSC following out-of-hospital cardiac arrest
1. In this randomized clinical trial, among patients who had an out-of-hospital cardiac arrest, no significant difference was found in...
Intraosseous drug administration does not improve survival in out of hospital cardiac arrest
1. In this randomized trial, intraosseous-first vascular access did not result in higher 30-day survival than intravenous-first strategies in adults...